EVO vs. MOR, ACAD, MLTX, SMMT, JANX, INDV, IDYA, ARWR, RYTM, and MRUS
Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include MorphoSys (MOR), ACADIA Pharmaceuticals (ACAD), MoonLake Immunotherapeutics (MLTX), Summit Therapeutics (SMMT), Janux Therapeutics (JANX), Indivior (INDV), IDEAYA Biosciences (IDYA), Arrowhead Pharmaceuticals (ARWR), Rhythm Pharmaceuticals (RYTM), and Merus (MRUS). These companies are all part of the "pharmaceutical preparations" industry.
MorphoSys (NASDAQ:MOR) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.
MorphoSys received 22 more outperform votes than Evotec when rated by MarketBeat users. However, 75.00% of users gave Evotec an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
MorphoSys presently has a consensus target price of $11.78, suggesting a potential downside of 32.14%. Evotec has a consensus target price of $11.00, suggesting a potential upside of 111.54%. Given MorphoSys' stronger consensus rating and higher probable upside, analysts clearly believe Evotec is more favorable than MorphoSys.
Evotec has a net margin of 0.00% compared to Evotec's net margin of -80.07%. MorphoSys' return on equity of 0.00% beat Evotec's return on equity.
In the previous week, Evotec had 20 more articles in the media than MorphoSys. MarketBeat recorded 30 mentions for Evotec and 10 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.32 beat Evotec's score of 0.29 indicating that Evotec is being referred to more favorably in the news media.
Evotec has higher revenue and earnings than MorphoSys.
MorphoSys has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Evotec beats MorphoSys on 11 of the 15 factors compared between the two stocks.
Get Evotec News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
